Par, Mylan launch generic Tambocor
Par has launched a generic version of 3M's antiarrhythmic Tambocor (flecainide) and has received marketing exclusivity (1"The Pink Sheet" May 6, In Brief). Mylan has also begun shipments of generic Tambocor after licensing the product from 3M...
You may also be interested in...
A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
Efficacy against moderate to severe/critical COVID-19 was 66%-67%, well above the FDA’s stated 50% efficacy threshold for an EUA but far short of the 94%+ efficacy rates posted by the Pfizer and Moderna vaccines against symptomatic disease; agency says efficacy against specific variants cannot be evaluated at this time because sequencing data are incomplete.